A highly durable RNAi therapeutic inhibitor of PCSK9

Cited by (775)

Items 201–300 of 775

1. Nanoparticles and siRNA: a new era in therapeutics?
   Pérez-Carrión, María Dolores, Posadas, Inmaculada, Ceña, Valentín · 2024 · Pharmacological Research
2. Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
   Stefano Spolitu, Wen Dai, John A. Zadroga, Lale Özcan · 2019 · Current Opinion in Lipidology
3. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
   L. M. Strilchuk, Federica Fogacci, Arrigo F.G. Cicero · 2019 · Expert Opinion on Drug Safety
4. Inclisiran in lipid management: A Literature overview and future perspectives
   Pietro Scicchitano, Michele Milo, Rosanna Mallamaci, Micaela De Palo, Pasquale Caldarola, Francesco Massari, Domenico Gabrielli, Furio Colivicchi, Marco Matteo Ciccone · 2021 · Biomedicine & Pharmacotherapy
5. Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
   Ricarda C. Steffens, Ernst Wagner · 2022 · Pharmaceutical Research
6. Shorter Is Better: The α-( l )-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs
   Shigeo Matsuda, Saikat Bala, Jen-Yu Liao, Dhrubajyoti Datta, Atsushi Mikami, Lauren Blair Woods, Joel M. Harp, Jason A. Gilbert, Anna Bisbe, Rajar M. Manoharan et al. · 2023 · Journal of the American Chemical Society
7. Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics
   Mai B. Thayer, Julie M. Lade, David R. Doherty, Fang Xie, Babak Basiri, Omar S. Barnaby, Noor S. Bala, Brooke M. Rock · 2019 · Scientific Reports
8. Keep recycling going: new approaches to reduce LDL-C
   Klein-Szanto, Andres J.P., Bassi, Daniel E. · 2019 · Biochemical Pharmacology
9. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
   Natalie Arnold, Wolfgang Köenig · 2022 · Current Cardiology Reports
10. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis
    Yenilmez, Batuhan, Wetoska, Nicole, Kelly, Mark, Echeverria, Dimas, Min, Kyounghee, Lifshitz, Lawrence, Alterman, Julia F., Hassler, Matthew R., Hildebrand, Samuel, DiMarzio, Chloe et al. · 2022 · Molecular Therapy
11. PCSK9: from biology to clinical applications
    Valentin Blanchard, Ilya Khantalin, Stéphane Ramin‐Mangata, Kévin Chemello, Brice Nativel, Gilles C. Lambert · 2018 · Pathology
12. A balanced evaluation of the evidence for adult neurogenesis in humans: implication for neuropsychiatric disorders
    Alvaro Duque, Reynold Spector · 2019 · Brain Structure and Function
13. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
    Toshiyuki Nishikido · 2023 · Cardiovascular Diabetology
14. A Critical Review of the Efficacy and Safety of Inclisiran
    Hardy, Jennifer, Niman, Stephanie, Pereira, Edward, Lewis, Todd, Reid, Jessica, Choksi, Rushab, Goldfaden, Rebecca F. · 2021 · American Journal of Cardiovascular Drugs
15. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
    Sinning, David, Landmesser, Ulf · 2020 · Current Cardiology Reports
16. Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery
    Wei Wang, Defang Ouyang · 2022 · Drug Discovery Today
17. Structural Modifications of siRNA Improve Its Performance In Vivo
    Ivan V. Chernikov, Ul’yana A. Ponomareva, Elena L. Chernolovskaya · 2023 · International Journal of Molecular Sciences
18. RNA Therapeutics: How Far Have We Gone?
    Maria Francisca Coutinho, Liliana Matos, Juliana Inês Santos, Sandra Alves · 2019 · Advances in experimental medicine and biology
19. Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis
    Maristella Donato, Nicola Ferri, Maria Giovanna Lupo, Elisabetta Faggin, Marcello Rattazzi · 2020 · International Journal of Molecular Sciences
20. Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
    Wołowiec, Łukasz, Osiak, Joanna, Wołowiec, Anna, Wijata, Aleksandra, Grześk, Elżbieta, Kozakiewicz, Mariusz, Banach, Joanna, Nowaczyk, Alicja, Nowaczyk, Jacek, Grześk, Grzegorz · 2023 · Pharmaceutics
21. RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
    Philipp Schaible, Wolfgang Andreas Bethge, Claudia Lengerke, Réka Ágnes Haraszti · 2022 · Cancer Research
22. Gene therapy for monogenic disorders: challenges, strategies, and perspectives
    Yi Zhang, Zhi‐Ying Wu · 2023 · Journal of genetics and genomics/Journal of Genetics and Genomics
23. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
    Daniel Gaudet, Jean‐Philippe Drouin‐Chartier, Patrick Couture · 2017 · Canadian Journal of Cardiology
24. An update on pharmacotherapies in diabetic dyslipidemia
    Manasvi Gupta, Ramyashree Tummala, Raktim Kumar Ghosh, Colin Blumenthal, Karan Philip, Dhrubajyoti Bandyopadhyay, Héctor O. Ventura, PRAKASH C. DEEDWANIA · 2019 · Progress in Cardiovascular Diseases
25. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models
    Nadine Haase, Donald J. Foster, Mark Cunningham, Julia Bercher, Tuyen M Nguyen, Svetlana Shulga‐Morskaya, Stuart Milstein, Sarfraz Shaikh, Jeff Rollins, Michaela Golić et al. · 2020 · Journal of Clinical Investigation
26. The evolving landscape of PCSK9 inhibition in cancer
    Palak P. Oza, Khosrow Kashfi · 2023 · European Journal of Pharmacology
27. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    Petra El Khoury, Sandy Elbitar, Youmna Ghaleb, Yara Abou Khalil, Mathilde Varret, Cathérine Boileau, Marianne Abifadel · 2017 · Current Atherosclerosis Reports
28. Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo
    Vivek Sharma, Maire F. Osborn, Matthew R. Hassler, Dimas Echeverria, Socheata Ly, Egor A. Ulashchik, Yury V. Martynenko-Makaev, Vadim V. Shmanai, Timofei S. Zatsepin, Anastasia Khvorova et al. · 2018 · Bioconjugate Chemistry
29. Novel Therapeutic Targets for Managing Dyslipidemia
    Vasanth Sathiyakumar, Karan Kapoor, Steven Richard Jones, Maciej Banach, Seth Shay Martin, Peter Paul Toth · 2018 · Trends in Pharmacological Sciences
30. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
    Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, Alberto Corsini · 2024 · Journal of Clinical Medicine
31. Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands
    Jeffrey T. Bagdanoff, Thomas M. Smith, Martin Allan, Peter H. O’Donnell, Zachary Nguyen, Elizabeth A. Moore, Jason Baird, Shuangxi Wang, Vanitha Subramanian, Bruno Tigani et al. · 2023 · Cell chemical biology
32. Metabolically Stable Anomeric Linkages Containing GalNAc–siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways
    Kandasamy Pachamuthu, S. Mori, Shigeo Matsuda, Namrata D. Erande, Dhrubajyoti Datta, Jennifer L. S. Willoughby, Nate Taneja, Jonathan O′Shea, Anna Bisbe, Rajar M. Manoharan et al. · 2023 · Journal of Medicinal Chemistry
33. Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases
    Harshini Kurakula, Swetha Vaishnavi, Mohammed Yaseen Sharif, Satheesh Ellipilli · 2023 · ACS Omega
34. PCSK9 inhibitors: current status and emerging frontiers in lipid control
    Federica Giuseppa Agnello, Maria Sara Mauro, Carla Rochira, Davide Landolina, Simone Finocchiaro, Antonio Greco, Nicola Ammirabile, Carmelo Raffo, Placido Maria Mazzone, Marco Spagnolo et al. · 2023 · Expert Review of Cardiovascular Therapy
35. A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights
    Parham Soufizadeh, Vahid Mansouri, Naser Ahmadbeigi · 2024 · Laboratory Animal Research
36. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
    Amir Abbas Momtazi‐Borojeni, Maciej Banach, Matteo Pirro, Evan A. Stein, Amirhossein Sahebkar · 2017 · Clinical Reviews in Allergy & Immunology
37. An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema
    Jingxuan Liu, June Qin, Anna Borodovsky, Timothy Racie, Adam B. Castoreno, Mark K. Schlegel, Martin A. Maier, Tracy Zimmerman, Kevin J. Fitzgerald, James Thomas Butler et al. · 2018 · RNA
38. An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides
    Ysobel R. Baker, Cameron Thorpe, Jinfeng Chen, Laura M. Poller, Lina Cox, Pawan Kumar, Wooi Fang Lim, Lillian Lie, Graham McClorey, Sven Epple et al. · 2022 · Nature Communications
39. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
    Ebenezer, Oluwakemi, Comoglio, Pietro, Wong, Gane Ka-Shu, Tuszynski, Jack A. · 2023 · International Journal of Molecular Sciences
40. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
    Agnello, Federica, Ingala, Salvatore, Laterra, Giulia, Scalia, Lorenzo, Barbanti, Marco · 2024 · Journal of Clinical Medicine
41. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
    Binbin Zheng-Lin, Alberto Ortíz · 2018 · Drugs
42. Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin
    Esteban A. Orellana, Ahmed M. Abdelaal, Loganathan Rangasamy, Srinivasarao Tenneti, Sunghyun Myoung, Philip Stewart Low, Andrea L. Kasinski · 2019 · Molecular Therapy — Nucleic Acids
43. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
    Makan Khoshnejad, Ami R. Patel, Krzysztof Wojtak, Sagar B. Kudchodkar, Laurent M. P. F. Humeau, Nicholas N. Lyssenko, Daniel James Rader, Kar Muthumani, David B. Weiner · 2018 · Molecular Therapy
44. Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands
    Linda C. Zuurbier, Joep C. Defesche, Albert Wiegman · 2021 · Genes
45. Strategies to Overcome Residual Risk During Statins Era
    Kyoung Im Cho, Jongwook Yu, Toshio Hayashi, Seung Hwan Han, Kwang Kon Koh · 2019 · Circulation Journal
46. Targeting angiotensinogen with RNA-based therapeutics
    Liwei Ren, Katrina M. Mirabito Colafella, Dominique M. Bovée, Estrellita Uijl, A.H. Jan Danser · 2019 · Current Opinion in Nephrology & Hypertension
47. Single-Stranded Phosphorothioated Regions Enhance Cellular Uptake of Cholesterol-Conjugated siRNA but Not Silencing Efficacy
    Socheata Ly, Dimas Echeverria, Jacquelyn Sousa, Anastasia Khvorova · 2020 · Molecular Therapy — Nucleic Acids
48. siRNA drug Leqvio (inclisiran) to lower cholesterol
    Julia M. Migliorati, Jing Jin, Xiao‐bo Zhong · 2022 · Trends in Pharmacological Sciences
49. Genome Editing
    Kiran Musunuru · 2017 · Journal of the American College of Cardiology
50. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
    Wilkinson, Michael J., Bajaj, Archna, Brousseau, Margaret E., Taub, Pam R. · 2024 · Journal of the American Heart Association
51. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
    Ping Wan, Siyuan Tang, Taihua Yang, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu et al. · 2025 · Atherosclerosis
52. 5′-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger
    Pawan Kumar, Rubina Giare Parmar, Christopher R. Brown, Jennifer L. S. Willoughby, Donald J. Foster, I. Ramesh Babu, Sally Schofield, Vasant Jadhav, Klaus Charissé, Jayaprakash K. Nair et al. · 2019 · Chemical Communications
53. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
    Reijman, M Doortje, Schweizer, Anja, Peterson, Amy L H, Bruckert, Eric, Stratz, Christian, Defesche, Joep C, Hegele, Robert A, Wiegman, Albert · 2022 · European Journal of Preventive Cardiology
54. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
    Wolfgang Köenig, Lorena Garcia Conde, Ulf Landmesser, Lawrence A. Leiter, Kausik Kumar Ray, Gregory G. Schwartz, R. Scott Wright, Jackie Han, Frederick Johan Raal · 2022 · Cardiovascular Drugs and Therapy
55. Alirocumab for the treatment of hypercholesterolemia
    Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2017 · Expert Opinion on Biological Therapy
56. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Bell, Andrew S., Wagner, Josephin, Rosoff, Daniel B., Lohoff, Falk W. · 2023 · Neuroscience & Biobehavioral Reviews
57. Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics
    Melisande Addison, Priyanga Diloshini Ranasinghe, David John Webb · 2023 · Hypertension
58. Deterioration of Organ Function As a Hallmark in Sepsis: The Cellular Perspective
    Michael W Bauer, Sina Maren Coldewey, Margit Leitner, Bettina Löffler, Sebastian Weis, Reinhard Wetzker · 2018 · Frontiers in Immunology
59. Small interfering ribonucleic acid for cholesterol lowering – Inclisiran
    Daniel E. Soffer, Robert M. Stoekenbroek, Roda Plakogiannis · 2022 · Journal of clinical lipidology
60. Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
    Yanan Wang, Dan Fang, Qinzhi Yang, Jingcan You, Liqun Wang, Jianbo Wu, Min Zeng, Mao Luo · 2023 · Frontiers in Immunology
61. Emerging oral therapeutic strategies for inhibiting PCSK9
    Nicola Ferri, Giorgia Marodin · 2024 · Atherosclerosis Plus
62. Targeting Therapeutic Oligonucleotides
    Arthur A. Levin · 2017 · New England Journal of Medicine
63. Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable <i>O</i>-Phosphocholine-<i>N</i>-docosahexaenoyl-<scp>l</scp>-serine siRNA Conjugate in Mouse Brain
    Nikan, Mehran, Osborn, Maire F., Coles, Andrew H., Biscans, Annabelle, Godinho, Bruno M.D.C., Haraszti, Reka A., Sapp, Ellen, Echeverria, Dimas, DiFiglia, Marian, Aronin, Neil et al. · 2017 · Bioconjugate Chemistry
64. Role of a “Magic” Methyl: 2′-Deoxy-2′-α-F-2′-β-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5′-Phosphate Mimics and Mitigation of Off-Target Effects
    Dale C. Guenther, S. Mori, Shigeo Matsuda, Jason A. Gilbert, Jennifer L. S. Willoughby, Sarah Hyde, Anna Bisbe, Yongfeng Jiang, Saket Agarwal, Mimouna Madaoui et al. · 2022 · Journal of the American Chemical Society
65. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
    Georgios Tsioulos, Dimitris C. Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Evangelia Kotsi, Gerasimos Socrates Christodoulatos, Dimitrios Tsilingiris, Ιrene Karampela, Alexandros Skourtis, Μaria Dalamaga · 2024 · International Journal of Molecular Sciences
66. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
    Brian Tomlinson, Nivritti G. Patil, Manson Fok, Christopher Wai Kei Lam · 2021 · Endocrinology and Metabolism
67. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
    Cicero, Arrigo F.G., Fogacci, Federica, Zambon, Alberto, Toth, Peter P., Borghi, Claudio · 2022 · American Heart Journal Plus: Cardiology Research and Practice
68. Moving Targets
    Lars E. Larsen, Robert M. Stoekenbroek, John J.P. Kastelein, Adriaan Georgius Holleboom · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
69. Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities
    Diane Ramsden, Jing‐Tao Wu, Brad R. Zerler, Sajida Iqbal, Jim Jiang, Valerie A. Clausen, Krishna Chaitanya Aluri, Yongli Gu, Sean Dennin, Joo‐Hwan Kim et al. · 2019 · Drug Metabolism and Disposition
70. Artificial Platelets for Efficient siRNA Delivery to Clear “Bad Cholesterol”
    Yanfen Zhang, Yuyan Qin, Huan Li, Qingsheng Peng, Ping Wang, Langyu Yang, Sheng Chen, Ming Li, Jijun Fu, Xiyong Yu et al. · 2020 · ACS Applied Materials & Interfaces
71. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
    Alexandra C. Chadwick, Kiran Musunuru · 2017 · Arteriosclerosis Thrombosis and Vascular Biology
72. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria
    Thomas A. Forbes, Bob D. Brown, Cheng-Jung Lai · 2021 · British Journal of Clinical Pharmacology
73. RNA Silencing in the Management of Dyslipidemias
    Neil C. Henney, Maciej Banach, Peter Edward Penson · 2021 · Current Atherosclerosis Reports
74. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
    Nicola Ferri, Massimiliano Ruscica, Maria Giovanna Lupo, Marco Vicenzi, Cesare Riccardo Sirtori, Alberto Corsini · 2022 · Pharmacological Research
75. Improved extracellular vesicle-based mRNA delivery for familial hypercholesterolemia treatment
    Zheng Yang, Panpan Ji, Zhelong Li, Rongxin Zhang, Mengying Wei, Yang Yang, Lijun Yuan, Yan Han, Guodong Yang · 2023 · Theranostics
76. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
    Shigeo Masuda, Shigeru Miyagawa, Yoshiki Sawa · 2017 · New England Journal of Medicine
77. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
    Oostveen, Reindert F., Khera, Amit V., Kathiresan, Sekar, Stroes, Erik S.G., Fitzgerald, Kevin, Harms, Matthew J., Oakes, Benjamin L., Kastelein, John J.P. · 2023 · Arteriosclerosis, Thrombosis, and Vascular Biology
78. Small circular interfering RNAs (sciRNAs) as a potent therapeutic platform for gene-silencing
    Hartmut Jahns, Rohan Degaonkar, Peter Podbevšek, Swati Gupta, Anna Bisbe, Krishna Chaitanya Aluri, John Szeto, Pawan Kumar, Sarah LeBlanc, Tim Racie et al. · 2021 · Nucleic Acids Research
79. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
    Porkizhi Arjunan, Durga Kathirvelu, Gokulnath Mahalingam, Ashish Goel, Uday George Zacharaiah, Alok Srivastava, Srujan Kumar Marepally · 2024 · Acta Pharmaceutica Sinica B
80. Robust genome and cell engineering via in vitro and in situ circularized RNAs
    Michael Tong, Nathan D. Palmer, Amir Dailamy, Aditya Kumar, Hammza Khaliq, Sangwoo Han, Emma N Finburgh, Madeleine K. Wing, Camilla Hong, Yichen Xiang et al. · 2024 · Nature Biomedical Engineering
81. Health and societal implications of medical and technological advances
    Victor J. Dzau, Celynne Balatbat · 2018 · Science Translational Medicine
82. Dawn of Epitranscriptomic Medicine
    Aikaterini Gatsiou, Konstantinos Stellos · 2018 · Circulation Genomic and Precision Medicine
83. The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation
    Nabil Georges Seidah, Michel Chrétien, Majambu Mbikay · 2018 · Current Opinion in Lipidology
84. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
    Kiran Musunuru · 2020 · Annual Review of Medicine
85. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
    Danielle Brito e Cunha, Ana Beatriz Teixeira Frederico, Tamiris Azamor, Juliana Gil Melgaço, Patrícia Neves, Ana Bom, Tatiana Martins Tilli, Sotiris Missailidis · 2022 · Pharmaceuticals
86. Circular RNA regulatory role in pathological cardiac remodelling
    Alessia Bibi, Monika Barteková, Shrey Gandhi, Simona Greco, Alisia Madè, Moumita Sarkar, Victoria Stopa, Spyros Tastsoglou, David de Gonzalo‐Calvo, Yvan Devaux et al. · 2024 · British Journal of Pharmacology
87. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes
    Leo Francis Buckley, Peter Libby · 2019 · Journal of Cardiovascular Pharmacology
88. Opportunities for an atherosclerosis vaccine: From mice to humans
    Payel Roy, Amal J. Ali, Kouji Kobiyama, Yanal Ghosheh, Klaus F. Ley · 2020 · Vaccine
89. Treatment of dyslipidemia in kidney transplantation
    Claudio E. Ponticelli, Lorenzo Arnaboldi, Gabriella Luisa Moroni, Alberto Corsini · 2020 · Expert Opinion on Drug Safety
90. Estimation of the major cardiovascular events prevention with Inclisiran
    Alberto Cordero, Carlos G. Santos‐Gallego, Lorenzo Fácila, Moisés Rodríguez‐Mañero, Vicente Bertomeu‐González, Jose Maria Castellano, José Seijas‐Amigo, Julio E. Núñez, Pilar Zuazola, José Ramón González‐Juanatey et al. · 2020 · Atherosclerosis
91. New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
    Ningning Ma, Lei Fan, Yunxia Dong, Xiaoding Xu, Chuwei Yu, Jing Chen, Jin Ren · 2021 · Pharmacological Research
92. RNA-based therapy in the management of lipid disorders: a review
    Dirk Jacobus Blom, Adrian David Marais, Rajen Moodley, Nico van der Merwe, Alet van Tonder, Frederick Johan Raal · 2022 · Lipids in Health and Disease
93. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials
    Min Luo, Yihan Liu, Xinyi Xu, Kai Liu, Chao Shen, Haoyang Hu, Zhiyao He, Fengbo Wu · 2023 · Frontiers in Pharmacology
94. Are PCSK9 Inhibitors Cost Effective?
    Max Joseph Korman, Kjetil Retterstøl, Ivar Sønbø Kristiansen, Torbjørn Fosen Wisløff · 2018 · PharmacoEconomics
95. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
    Ian J. Huggins, Carlos A. Medina, Aaron D. Springer, Arjen van den Berg, Satish G. Jadhav, Xian-Shu Cui, Steven F. Dowdy · 2019 · Molecules
96. USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages
    Vivian Weiwen Xue, Jeff Yat‐Fai Chung, Philip Chiu‐Tsun Tang, Alex Siu Wing Chan, Travis Hoi-Wai To, Justin Shing‐Yin Chung, Francis Mussal, Eric W.‐F. Lam, Chunjie Li, Ka‐Fai To et al. · 2021 · Molecular Therapy — Oncolytics
97. The promising novel therapies for familial hypercholesterolemia
    Ruoyu Chen, Shaoyi Lin, Xiaomin Chen · 2022 · Journal of Clinical Laboratory Analysis
98. Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects
    Andrew Vaillant · 2022 · Viruses
99. Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
    Alberto Corsini, Henry N. Ginsberg, M. John Chapman · 2025 · Pharmacology & Therapeutics
100. Novel lipid modifying drugs to lower LDL cholesterol
     Arjen J. Cupido, Laurens F. Reeskamp, John J.P. Kastelein · 2017 · Current Opinion in Lipidology